Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of PCSK9 Inhibitor Therapeutics

This educational content was derived from the American College of Physicians (ACP) Internal Medicine Meeting 2017 in San Diego, California. This activity will focus on optimized treatment plans for patients with dyslipidemia in the era of PCSK9 inhibitor therapeutics. LDL-C has been identified as an important therapeutic target to prevent the progression of atherosclerotic disease, however only 1 out of every 3 adults with high LDL-C has the condition under control. Expert faculty on this panel will discuss the science of PCSK9 inhibitors and aid physicians in the best practices to get their patients at LDL-C target.


This activity has been designed to meet the educational needs of cardiologists, internists, primary care physicians, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.


Upon completion of this activity, participants will be better able to do the following:

  1. Discuss the science of PCSK9 inhibitor therapeutics and the current ACC/AHA/NLA guidelines for patients with dyslipidemia.
  2. Analyze clinical trial data for PCSK9 inhibitor therapeutics.
  3. Integrate personalized treatment plans for patients with statin intolerance, familial hypercholesterolemia, and dyslipidemia patients not at LDL-C goal.


James A. Underberg, MD
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
President-Elect National Lipid Association
New York, New York

Michael J. Blaha, MD
Assistant Professor of Medicine
Johns Hopkins School of Medicine
Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Baltimore, Maryland

Elizabeth J. Jackson MSN, ACNS-BC, FNLA
Diplomate, Accreditation Council of Clinical Lipidology
Cardio Texas PLLC
St. David's Medical Center
Austin, Texas

Peter H. Jones, MD
Associate Professor Medicine
Center for Cardiovascular Disease Prevention
Co-Director, Lipid Metabolism and Atherosclerosis Clinic
Baylor College of Medicine
Houston, Texas

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
James A. Underberg, MD

Consultant/Advisor: Akcea Therapeutics; Amarin Corporation; Amgen Inc.; Invitae Corporation; Kastle Therapeutics; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC

Grant/Research Support: Aegerion Pharmaceuticals, Inc.; Pfizer Inc.

Speaker's Bureau: Alexion Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Kastle Therapeutics; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; True Health Diagnostics

Michael J. Blaha, MD

Consultant/Advisor: Amgen Inc.; Ferring Pharmaceuticals; MedImmune

Grant/Research Support: Aetna Foundation; Amgen Inc.; American Heart Association, Inc.

Elizabeth J. Jackson, MSN, ACNS-BC

Consultant/Advisor: Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC

Speaker's Bureau: Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC

Peter H. Jones, MD

Consultant/Advisor: Amgen Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC

Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski; Chelsey Benedek; and Megan Gentile hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Peer Review

This CME activity has been peer-reviewed by The American Journal of Medicine

Financial Support

This CME activity has been supported by an independent educational grant from Amgen Inc.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.


CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit(s)™
  • 2.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 2.00 AMA PRA Category 1 Credit(s)™
  • 2.00 Non-physician
Please login or register to take this course.